Hormonal
Newer anti-obesity medications (GLP-1 and GLP-1/GIP agonists like semaglutide and tirzepatide) produce significantly greater weight loss (15-22.5%) compared to lifestyle modifications alone, which typically yield modest and unsustainable results.
Newer GLP-1 and GLP-1/GIP medications (like semaglutide and tirzepatide) are significantly more effective for weight loss (15-22.5%) than lifestyle changes alone. However, access is difficult due to insurance coverage, supply shortages, and cost. These medications should be viewed as a tool to help manage obesity as a chronic disease, but they still require lifestyle support and are not a 'magic pill' without side effects or administrative burdens.
In contrast, bariatric surgery boasts 46%–74% excess weight loss 10 years post-operatively... Current literature indicates that only 12% of United States adults with a body mass index (BMI) > 25 kg/m2 receive adequate weight management care... approximately 95% were provided with lifestyle advice alone... Semaglutide 2.4 mg (a GLP-1) has demonstrated an average weight loss of 15% weight loss over 68 weeks... Tirzepatide (a GLP-1/GIP) has demonstrated an even greater average of 22.5% weight loss at 72 weeks
Why this rating
The paper cites large cohort studies and clinical trial data for efficacy, but the primary study is qualitative regarding patient/provider perspectives, not a new RCT.
Source
Primary care patient and practice member perspectives on weight loss medications: challenges and opportunities
Jodi Summers Holtrop et al. · Frontiers in Medicine · 2025
DOI 10.3389/fmed.2025.1584799
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →